鎌状赤血球症治療の世界市場レポート 2025年

鎌状赤血球症治療市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.7％で68億米ドルに成長します。予測期間の成長は、遺伝子編集と遺伝子治療、新薬開発、遠隔医療と遠隔モニタリング、世界ヘルスイニシアチブに起因すると考えられます。予測期間における世界の動向には、根治療法、代替疼痛管理、世界の協力関係、患者擁護と関与が含まれます。

輸血ニーズの高まりは、当面の鎌状赤血球症治療市場の拡大を促進すると予想されます。輸血は、ドナーからレシピエントへの血液または血液製剤の移送を伴う医療処置です。輸血は、血液の酸素運搬能力を高め、血管閉塞に伴う合併症を軽減することで、鎌状赤血球症（SCD）患者の治療に重要な役割を果たしています。たとえば、2022年12月、gov.UKによると、英国では2021年に献血が増加し、全国で170万件の献血が行われました。さらに2022年1月、Mid-Atlantic Long-Term Careによると、米国では1日に約29,000単位の赤血球、5,000単位の血小板、6,500単位の血漿が必要とされています。従って、輸血需要の増加が鎌状赤血球症治療市場成長の原動力となっています。

血液・骨髄移植の増加は、今後数年間の鎌状赤血球症治療市場の成長を牽引すると予想されます。血液・骨髄移植は、鎌状赤血球症のような疾患を治療するために、不健康な造血細胞を健康な造血細胞と置き換えることを含みます。この治療法には、患者自身の体から採取した健康な骨髄細胞を注入する方法（自家移植）と、ドナーから採取した健康な骨髄細胞を注入する方法（同種移植）があります。例えば、2024年6月、国立移植機構（ONT）は、スペインが2023年に骨髄ドナー登録に23,686人のドナーを追加し、2022年から8％増加したと報告しました。また、同国では造血幹細胞移植が3,717件と過去最高を記録し、人口100万人当たりの移植件数は77.4件となりました。その結果、血液移植と骨髄移植の普及率が上昇し、鎌状赤血球症治療市場を大きく押し上げると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界鎌状赤血球症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の鎌状赤血球症治療市場：成長率分析
• 世界の鎌状赤血球症治療市場の実績：規模と成長, 2019-2024
• 世界の鎌状赤血球症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界鎌状赤血球症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の鎌状赤血球症治療市場治療法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 輸血
• 薬物療法
• 骨髄移植
• 世界の鎌状赤血球症治療市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎌状赤血球貧血
• ヘモグロビン鎌状C病（HbSC）
• その他の病気の種類
• 世界の鎌状赤血球症治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の鎌状赤血球症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の鎌状赤血球症治療市場、輸血の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定期的な輸血
• 交換輸血
• 世界の鎌状赤血球症治療市場、薬物療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドロキシウレア
• L-グルタミン
• ボクセロター
• クリザンリズマブ
• 世界の鎌状赤血球症治療市場骨髄移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 同種移植
• 自家移植

第7章 地域別・国別分析

• 世界の鎌状赤血球症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の鎌状赤血球症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 鎌状赤血球症治療市場：競合情勢
• 鎌状赤血球症治療市場：企業プロファイル
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Baxter International Inc.
• Teva Pharmaceutical Industries Ltd.
• Vertex Pharmaceuticals Incorporated
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Silver Lake Research Corporation0.45
• Global Blood Therapeutics Inc.
• Acceleron Pharma Inc.
• Sangamo Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 鎌状赤血球症治療市場2029：新たな機会を提供する国
• 鎌状赤血球症治療市場2029：新たな機会を提供するセグメント
• 鎌状赤血球症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that impacts hemoglobin, a protein found in red blood cells. Individuals with sickle cell disease produce defective hemoglobin, known as hemoglobin S (HbS), due to a mutation in the hemoglobin gene. Treatment for sickle cell disease aims to alleviate blockages, improve blood flow, and repair damaged tissues.

The primary modalities for treating sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplant. A blood transfusion involves the transfer of blood or blood products from a donor to a recipient. Sickle cell disease encompasses various types, such as sickle cell anemia, hemoglobin sickle C disease (HbSC), and others, with treatment administered through oral and parenteral routes. End users of these treatments include hospitals, specialty clinics, and other healthcare facilities.

The sickle cell disease treatment market research report is one of a series of new reports from The Business Research Company that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.95 billion in 2024 to $3.54 billion in 2025 at a compound annual growth rate (CAGR) of 19.7%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy.

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $6.8 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to gene editing and gene therapy, new drug development, telemedicine and remote monitoring, global health initiatives. Major trends in the forecast period include curative therapies, pain management alternatives, global collaborations, patient advocacy and engagement.

The growing need for blood transfusions is expected to propel the expansion of the sickle cell disease treatment market in the foreseeable future. Blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. It plays a crucial role in the treatment of sickle cell disease (SCD) patients by enhancing the blood's oxygen-carrying capacity and reducing the complications associated with vaso-occlusion. For example, in December 2022, gov.UK reported that the UK witnessed an increase in blood donations in 2021, with 1.7 million donations made across the country. Moreover, in January 2022, according to Mid-Atlantic Long-Term Care, the United States requires approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma daily. Therefore, the growing demand for blood transfusions is a driving force behind the growth of the sickle cell disease treatment market.

The increasing number of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market in the coming years. A blood and bone marrow transplant involves replacing unhealthy blood-forming cells with healthy ones to treat conditions like sickle cell disease. This procedure can involve infusing healthy bone marrow cells either from the patient's own body (autologous transplant) or from a donor (allogeneic transplant). For example, in June 2024, the National Transplant Organization (ONT) reported that Spain added 23,686 donors to its Bone Marrow Donor Registry in 2023, an 8% increase from 2022. The country also achieved a record 3,717 hematopoietic stem cell transplants, translating to 77.4 transplants per million population. As a result, the rising prevalence of blood and bone marrow transplants is expected to significantly boost the sickle cell disease treatment market.

Leading companies in the sickle cell disease (SCD) treatment market are focusing on developing new oral suspension drugs to improve patient compliance, enhance drug efficacy, and provide more convenient treatment options, particularly for pediatric and elderly patients. Oral suspension drugs are liquid medications with solid particles suspended in a liquid, designed to make it easier for patients to swallow, especially children or those who have difficulty with pills. For example, in March 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, launched a room temperature-stable oral suspension of Hydroxyurea. This affordable SCD treatment is designed to increase accessibility in India, priced at less than 1% of imported alternatives. It offers precise dosing with oral syringes, providing a solution for patients of all ages without the need for cold storage.

In October 2022, Pfizer Inc., a pharmaceutical corporation headquartered in the United States, acquired Global Blood Therapeutics Inc. for $5.4 billion. This acquisition provides Pfizer with access to a premier sickle cell disease portfolio and pipeline, addressing the critical needs of an underserved patient population. Global Blood Therapeutics Inc. is a biopharmaceutical company based in the United States, specializing in the development and commercialization of therapies for individuals with sickle cell disease (SCD).

Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sickle Cell Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sickle cell disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sickle cell disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sickle cell disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant
• 2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
• 3) By Route Of Administration: Oral; Parenteral
• 4) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Blood Transfusion: Regular Blood Transfusion; Exchange Transfusion
• 2) By Pharmacotherapy: Hydroxyurea; L-Glutamine; Voxelotor; Crizanlizumab
• 3) By Bone Marrow Transplant: Allogeneic Transplant; Autologous Transplant
• Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Sickle Cell Disease Treatment Market Characteristics

3. Sickle Cell Disease Treatment Market Trends And Strategies

4. Sickle Cell Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Sickle Cell Disease Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Sickle Cell Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Sickle Cell Disease Treatment Market Growth Rate Analysis
• 5.4. Global Sickle Cell Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Sickle Cell Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Sickle Cell Disease Treatment Total Addressable Market (TAM)

6. Sickle Cell Disease Treatment Market Segmentation

• 6.1. Global Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant
• 6.2. Global Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sickle Cell Anemia
• Hemoglobin Sickle C Disease (HbSC)
• Other Disease Types
• 6.3. Global Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.5. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Blood Transfusion
• Exchange Transfusion
• 6.6. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Pharmacotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydroxyurea
• L-Glutamine
• Voxelotor
• Crizanlizumab
• 6.7. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Bone Marrow Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Allogeneic Transplant
• Autologous Transplant

7. Sickle Cell Disease Treatment Market Regional And Country Analysis

• 7.1. Global Sickle Cell Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Sickle Cell Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sickle Cell Disease Treatment Market

• 8.1. Asia-Pacific Sickle Cell Disease Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sickle Cell Disease Treatment Market

• 9.1. China Sickle Cell Disease Treatment Market Overview
• 9.2. China Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sickle Cell Disease Treatment Market

• 10.1. India Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sickle Cell Disease Treatment Market

• 11.1. Japan Sickle Cell Disease Treatment Market Overview
• 11.2. Japan Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sickle Cell Disease Treatment Market

• 12.1. Australia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sickle Cell Disease Treatment Market

• 13.1. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sickle Cell Disease Treatment Market

• 14.1. South Korea Sickle Cell Disease Treatment Market Overview
• 14.2. South Korea Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sickle Cell Disease Treatment Market

• 15.1. Western Europe Sickle Cell Disease Treatment Market Overview
• 15.2. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sickle Cell Disease Treatment Market

• 16.1. UK Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sickle Cell Disease Treatment Market

• 17.1. Germany Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sickle Cell Disease Treatment Market

• 18.1. France Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sickle Cell Disease Treatment Market

• 19.1. Italy Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sickle Cell Disease Treatment Market

• 20.1. Spain Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sickle Cell Disease Treatment Market

• 21.1. Eastern Europe Sickle Cell Disease Treatment Market Overview
• 21.2. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sickle Cell Disease Treatment Market

• 22.1. Russia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sickle Cell Disease Treatment Market

• 23.1. North America Sickle Cell Disease Treatment Market Overview
• 23.2. North America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sickle Cell Disease Treatment Market

• 24.1. USA Sickle Cell Disease Treatment Market Overview
• 24.2. USA Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sickle Cell Disease Treatment Market

• 25.1. Canada Sickle Cell Disease Treatment Market Overview
• 25.2. Canada Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sickle Cell Disease Treatment Market

• 26.1. South America Sickle Cell Disease Treatment Market Overview
• 26.2. South America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sickle Cell Disease Treatment Market

• 27.1. Brazil Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sickle Cell Disease Treatment Market

• 28.1. Middle East Sickle Cell Disease Treatment Market Overview
• 28.2. Middle East Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sickle Cell Disease Treatment Market

• 29.1. Africa Sickle Cell Disease Treatment Market Overview
• 29.2. Africa Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sickle Cell Disease Treatment Market Competitive Landscape And Company Profiles

• 30.1. Sickle Cell Disease Treatment Market Competitive Landscape
• 30.2. Sickle Cell Disease Treatment Market Company Profiles
  • 30.2.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Sickle Cell Disease Treatment Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca plc
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. Amgen Inc.
• 31.7. Baxter International Inc.
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Vertex Pharmaceuticals Incorporated
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Ionis Pharmaceuticals Inc.
• 31.12. Silver Lake Research Corporation0.45
• 31.13. Global Blood Therapeutics Inc.
• 31.14. Acceleron Pharma Inc.
• 31.15. Sangamo Therapeutics Inc.

32. Global Sickle Cell Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sickle Cell Disease Treatment Market

34. Recent Developments In The Sickle Cell Disease Treatment Market

35. Sickle Cell Disease Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Sickle Cell Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Sickle Cell Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Sickle Cell Disease Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer